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Background: Triple negative breast cancer (TNBC) in humans is defined by the absence of oestrogen receptor (ER),
progesterone receptor (PR) and HER2 overexpression. Mammalian target of rapamycin (mTOR) is overexpressed in
TNBC and it represents a potential target for the treatment of this aggressive tumour. Feline mammary carcinoma
(FMC) is considered to be a model for hormone-independent human breast cancer. This study investigated mTOR
and p-mTOR expression in FMC in relation to triple negative (TN) phenotype.
Results: The expression of mTOR, p-mTOR, ERα, PR and HER2 was evaluated in 58 FMCs by immunohistochemistry
and in six FMC cell lines by Western blot analysis. 53.5% of FMC analyzed were ER, PR, HER2 negative (TN-FMC)
while 56.9% and 55.2% of cases expressed mTOR and p-mTOR respectively. In this study we found that m-TOR and
p-mTOR were more frequently detected in TN-FMC and in HER2 negative samples.
Conclusions: In this study, we demonstrate that there is also a FMC subset defined as TN FMC, which is
characterised by a statistically significant association with m-TOR and p-mTOR expression as demonstrated in
human breast cancer.Background
Triple negative breast cancer (TNBC) in humans is a
distinct subset of breast cancer that is defined by the
lack of immunohistochemical (IHC) expression of the
oestrogen receptor (ER) and progesterone receptor (PR)
and a lack of human epidermal growth factor receptor 2
(HER2) overexpression [1]. This subtype of cancer com-
prises 15-20% of patients with breast cancer for which
targeted therapy is currently unavailable [2,3]. To develop
new targeted therapies for this subset of tumours, re-
searchers focused their attention on the different intra-
cellular cell signaling pathways responsible for tumour
growth, invasion and metastasis in TNBC [4]. One of the
most pathways studied is the PI3K/AKT/mTOR pathway,
which can be activated by different membrane tyrosine
kinase receptors, including the epidermal growth factor* Correspondence: lorella.maniscalco@unito.it
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distribution, and reproduction in any medium(EGFR) family of growth receptors, insulin-like growth
factor receptor (IGF-R) and ERα [5].
A key downstream component of the PI3K pathway is
the mammalian target of rapamycin (mTOR), a serine/
threonine kinase involved in tumour formation and pro-
gression [3]. mTOR is activated by phosphorylation at
Ser2448 via the PI3K kinase/AKT signalling pathway and
is autophosphorylated at Ser2481 [6]. mTOR has two
main downstream messengers, the ribosomal p70 S6
kinase (S6K1) and the eukaryotic translation initiation
factor 4E-binding protein (4E-BP1) [7]. The activation of
S6K1 and 4E-BP1 by mTOR induces mRNA translation
and a subsequent increase in protein synthesis that is
essential for cell growth and proliferation [8,9].
Based on its role in tumour formation and progression,
targeted therapy against mTOR has been shown to de-
crease tumour growth in model systems [10,11] and sev-
eral mTOR inhibitors, such as everolimus, deforolimus
and temsirolimus, have been used in clinical trials fortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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cancer [12].
Recently, it has been reported that the activated form of
mTOR, phospho-mTOR (p-mTOR), detected at nuclear
level, was expressed more frequently in triple negative
(TN) human breast cancers compared with non-TN can-
cers [3], suggesting that mTOR may play a more import-
ant role in the progression of TNBC and could be
considered a new target for the treatment of this tumour
sub-type [9,13-15].
Feline mammary carcinoma (FMC) shares many bio-
logical and molecular similarities with human breast
cancer [16] and is considered an excellent model for ag-
gressive, hormone-independent human breast cancers
overexpressing HER2 [17-19]. The percentage of FMCs
that are negative for ER and PR range from 37% [20] to
54.2% [21]. Regarding HER2 expression in feline mam-
mary carcinomas scientific data are controversial. Some
authors [19,22,23] showed that HER2 is expressed from
39% to 56.3% which is similar to human breast cancer
(20-30%) [24] while Rasotto and colleagues [25] showed
HER2 expression in only the 5% of analyzed cases. We
have recently found that AKT is expressed in FMCs,
and its expression correlated with poor prognosis [22],
suggesting a role for the PI3K/AKT/mTOR pathway in
FMC pathogenesis.
The aim of this study was to investigate the role of
mTOR and p-mTOR in feline mammary tumours and
cell lines with regard to the TN FMC status and clinical
outcome to understand the role of mTOR in feline
mammary tumour progression and to evaluate whether
the feline model may be considered the first animal model
for the TNBC.
Methods
Tissue samples and histology
Tissue samples from 58 cases of FMC, 18 benign lesions
and 8 normal mammary tissues were collected from the
2000–2008 archives of the Diagnostic Laboratories of
the Department of Veterinary Sciences of the University
of Turin, Italy, and the Department of Animal Pathology,
University of Córdoba, Spain. Details of age, breed, ovari-
ectomy status and tumour size data were retrieved from
the hospital database. Postoperative clinical, radiological
and echographic examinations at 6, 12, 18 and 24 months
after surgery were performed by veterinarians to detect
the presence of distant organ metastases or the local re-
currence of the primary tumour. Animals that died due to
mammary carcinoma were submitted for post-mortem
examination to confirm the pathological diagnosis; sub-
jects that died of non-tumour-related causes (confirmed
by necroscopy) during the follow-up period were excluded
from the study. The disease-free interval (DFI) was consid-
ered to be the number of days between surgery andtumour recurrence and/or evidence of metastatic disease
while the overall survival (OS) was considered the period
between surgery and animal death. Normal mammary tis-
sue used as control were collected from necroscopy (after
owners’ consensus) of female cats that were neither spayed
nor treated with hormonal therapy during their life and
died spontaneously at the Veterinary Hospital of the
University of Turin.
The samples were fixed in 4% neutral buffered formalin,
paraffin embedded, sectioned at 4 μm and stained with
haematoxylin and eosin. Tumours were examined histo-
logically and classified according to the World Health
Organization (WHO) classification for tumours of domes-
tic animals [26]. Carcinomas were classified by differenti-
ation status [27] and surgical margins were evaluated to
confirm that all masses were completely surgically ablated.
Immunohistochemistry
IHC analysis was performed on 4 micron paraffin sections
from all mammary tissue samples collected. Endogenous
peroxidase activity was blocked with 3% hydrogen per-
oxide in methanol for 20 min at room temperature. The
sections were subjected to high-temperature antigen
unmasking by incubation with 98°C citric acid buffer
(pH 6.0). Primary anti-human antibodies were used
against mTOR (rabbit polyclonal antibody; catalogue
number 2983, Cell Signaling Technology; diluted 1:50,
overnight incubation), phospho-mTORSer2448-49F9
(rabbit polyclonal antibody; catalogue number 2976,
Cell Signaling Technology; diluted 1:50, overnight incuba-
tion), c-erbB-2 oncoprotein (rabbit polyclonal antibody,
Dako; 1:200 dilution; 1 h of incubation), PR (mouse mo-
noclonal antibody, clone PR10A9 IgG2A, Immunotech
Laboratories; 1:750 dilution, overnight incubation) and
ERα (rabbit polyclonal, Zymed Invitrogen; 1:80 dilution;
1 h of incubation). Antibodies were detected with avidin-
biotin peroxidase complex techniques using the Vectastain
Elite ABC kit (Vector Laboratories). External positive con-
trols were paraffin-embedded sections of MCF7 cells for
mTOR and p-mTOR [28], a human breast carcinoma
positive for HER2 and feline normal uterus for ERα and
PR. Specificity of primary antibody was carried out incu-
bating primary antibody with excess of specific peptide
used to immunize rabbits (available from Cell Signaling
Technology). After incubation the protein labeling was
abrogated by the previous incubation of antibodies with
the peptide.
The immunolabelled slides were randomised and masked
for blinded examination, which was performed independ-
ently by three observers (LM, SI and YM); when there was
disagreement (<5% of the slides), a consensus was obtained
using a multi-head microscope. Slides with >20% tumour
immunolabelled cells were considered to be positive for
mTOR and phospho-mTOR [3]. HER2 immunoreactivity
Figure 1 DFI in patients with TN and no-TN feline mammary
carcinomas. Kaplan–Meier estimates for disease free interval
probability in TN-FMCs (TN) and no TN_FMCs (no-TN) (P >0.05).
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which is commonly used in human pathology and also
adopted for FMCs [29]. ERα and PR positivity was evalu-
ated as described previously [22].
Cell lines and Western blot analysis
Six feline mammary tumour cell lines were evaluated:
FYCp, P248m, FMCp, FMCm, FKNp and FNNm; the
last four cell lines were kindly provided by Professor
Sasaki, Japan [30]. P248m cell lines derived from a pul-
monary metastasis of primary tubulopapillary mammary
carcinomas [31] while FYC cell lines derived from
tubulopapillary FMC [19,32,33]. Regarding cell lines
kindly provided by Dr. Sasaki please see the reference
[34]. The letters ‘p’ and ‘m’ indicate cell lines derived from
primary and metastatic lesions, respectively. FYCp, FMCp,
FMCm, FKNp and FNNm cells were grown in Roswell
Park Memorial Institute (RPMI) medium, whereas P248m
was grown in Dulbecco’s modified Eagle’s medium
(DMEM). In all cases, the medium was supplemented with
10% fetal calf serum, 100 μg/ml penicillin, 100 μg/ml
streptomycin and 1.5 mg/ml amphotericin B. For P248
cells, 10 μg/ml insulin was added to the DMEM.
Total protein were extracted at 80% of cellular conflu-
ence in boiling lysis buffer containing 1% sodium dodecyl
sulphate (SDS) and 0.1 M Tris HCl (pH 6.8). Total pro-
teins from each sample (40 μg) were separated on an 8%
SDS-polyacrylamide (PAGE) gel and transferred onto a
Hybond-C Extra membrane (Amersham Biosciences).
Membranes were blocked at room temperature for 2 h
with Tris-buffered saline (TBS, 10 mM Tris, 150 mM
NaCl, pH 7.4) containing 10% bovine serum albumin, then
incubated overnight at 4°C with the appropriate primary
antibodies, including anti-ER, PR, HER2, mTOR (see
antibodies used in IHC), phospho-mTORSer2448
(rabbit polyclonal antibody; catalogue number 2971;
Cell Signaling Technology) or α-tubulin (mouse mono-
clonal antibody; catalogue number 3873; Cell Signaling
Technology). After incubating with a horseradish
peroxidase-linked secondary antibody that was diluted
1:2000 in TBS-Tween, the membranes were washed in
TBS-Tween for 30 min and incubated with an enhanced
chemiluminescence reagent (Super Signal West Pico
Mouse IgG Detection Kit, Thermo Scientific). The pro-
teins were visualised by exposing the membrane to a
Hyperfilm ECL autoradiography film. Every experiment
was carried out in triplicate and bands intensity was an-
alyzed by using Biorad ChemiDoc XRS and ChemiDoc
MP imaging system software.
Statistical analysis
The IHC results were grouped into contingency tables
and analysed using Fisher’s exact or χ2 tests. The DFI and
OS analyses were performed using the Kaplan Meiermethod with a log rank test. P ≤0.05 was considered to be
statistically significant. The data were analysed using
GraphPad Prism Software v. 4.0.Results
Clinicopathologic characteristics
The mean age of cats at the time of diagnosis was 11.32 ±
2.69 years (range 6–18 years). Of the 58 animals, 11/58
(19.0%) were spayed and 4/58 (6.9%) were cyclically
treated with progesterone. At the time of diagnosis, histo-
logically confirmed lymph node metastases were present
in 5/58 (8.6%) FMC cases and no clinically and radio-
graphically observable distant organ metastases were
present. Of the 58 animals diagnosed with FMC, 13
(22.4%) did not present tumour recurrence and 45 (77.6%)
relapsed 2–23 months after surgery. The mean DFI was
196.4 ± 153.1 days. Information regarding the OS was
available for 25 cases within a 24 months follow-up period.
Eighteen patients presented distant organ metastases dur-
ing the follow up period and died of cancer-related causes
confirmed at post-mortem examination.
The mean gross size of the tumours was 2.3 ± 1.8 cm
and 15/58 (25.9%) tumours were ≤1.0 cm in diameter.
All tumours were surgically completely ablated, which
was confirmed histopathologically. A total of 39/58
(67.2%) tumours were tubulopapillary carcinoma, 11/58
(19.0%) were solid carcinoma, 7/58 (12.1%) were cri-
briform carcinomas and 1/58 (1.7%) was mucinous car-
cinoma. According to histological classification, 9/58
(15.5%) tumours were grade I, 24/58 (41.4%) were grade
II and 25/58 (43.1%) were grade III. Out of the 18 be-
nign mammary lesions used as controls, eight were
lobular hyperplasia, five were fibroadenomas and five
were simple adenomas.
Figure 2 mTOR expression in tubulopapillary carcinoma. a. Mammary gland. I grade tubulopapillary carcinoma. Neoplastic cells are
characterised by diffuse and moderate cytoplasmic immunopositivity for mTOR. Streptavidin-biotin-peroxidase method. Mayer’s haematoxylin
counterstaining. Scale bar = 50 μM b. Mammary gland. III grade tubulopapillary carcinoma. Neoplastic cells are characterised by diffuse and
moderate cytoplasmic immunopositivity for mTOR. Streptavidin-biotin-peroxidase method. Mayer’s haematoxylin counterstaining. Scale
bar = 50 μM.
Figure 3 - phospho-mTOR expression in tubulopapillary
carcinoma. Mammary gland. III grade tubulopapillary carcinoma.
About 60% of neoplastic cells are characterised by strong nuclear
immunopositivity for p-mTOR. Streptavidin-biotin-peroxidase
method. Mayer’s haematoxylin counterstaining. Scale bar = 100 μM.
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Immunoreactive products to ER monoclonal antibody in
feline uterus used as positive control were observed in
the nuclei of epithelial and stromal cells of the endomet-
rium and the nuclei of smooth muscle myometrial cells.
Immunoreactive products to PR monoclonal antibody in
feline uterus used as control were observed in the nuclei
of stromal cells and in the surface and glandular epithe-
lial cells of the endometrium and of smooth muscle cells
of the myometrium. In the normal mammary glands and
in the mammary tumors object of this study immunore-
active products to ER and PR were observed in the nuclei
of acinar and ductal glandular epithelial cells.
The human mammary carcinoma used as control for
HER2 demonstrated a strong complete membrane staining
in all the tumoral cells (HerceptTest 3+) while in feline
mammary carcinomas, immunoreactive products were seen
in the membrane and the cytoplasm of neoplastic cells and,
according to HerceptTest method, only complete mem-
brane staining was considered positive.
Based on the lack of the IHC expression of ER and the
PR, as well as the lack of HER2 overexpression, 31/58
(53.4%) cases were TN-FMC and 27/58 (46.6%) were
non-TN-FMC. Considering the immunophenotype of
the steroid receptors, we found that 46/58 (79.31%) were
ER-/PR-, 3/58(5.17%) were ER+/PR-, 6/58 (10.34%) were
ER-/PR + and 3 were ER+/PR+. None of the feline benign
mammary lesions, including the normal mammary tissue
analysed, were of triple negative subtype. TN-FMCs
compared to not TN-FMCs did not presented statistically
significative differences in terms of clinicopathological
features. The mean DFI observed in patients with TN
lesions was shorter than the DFI reported in patients with
non-TN cancer (150 days vs. 250) but not statistically
significant (P >0.05) such as OS (Figure 1).
Immunoreactive products in paraffine-embedded sec-
tions of MCF7 cells, used as control for mTOR and
p-mTOR, were seen in the 100% of the stained cells inthe cytoplasm and in both the cytoplasm and nuclei re-
spectively. Positive mTOR expression was detected in the
cytoplasm of neoplastic cells by IHC analysis (Figures 2a
and 2b) and was uniformly distributed within the tumour
mass. Expression of p-mTOR was detected more fre-
quently in the nucleus (Figure 3) and was also located in
the cytoplasm. According to Walsh and colleagues [3],
only the nuclear and peri-nuclear location was considered
to be positive. When not diffusely located within tumour
cells, p-mTOR was present in luminal epithelial cells. A
statistically significant positive association was found
between mTOR and p-mTOR expression (P <0.05). In
benign lesions, three cases showed cytoplasmic positiv-
ity for mTOR (two fibroadenoma and one adenoma),
while none of the benign lesions were p-mTOR posi-
tive. The normal feline mammary tissues were mTOR
and p-mTOR negative.
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p-mTOR, tumour characteristics and TN status. mTOR
and p-mTOR were more frequently detected in TN com-
pared with non-TN samples (P <0.05 for mTOR; P <0.001
for p-mTOR). There were no significant differences be-
tween the DFIs and OS analysis in relation to mTOR and
p-mTOR expression. We also evaluated if the high ex-
pression of m-TOR and p-mTOR found in our samples
was correlated to HER2, PR and ER expression expres-
sion. We found that samples HER2 negatives are statis-
tically correlated to samples p-mTOR (P < 0.001) and




n (%) n (%)
Triple negative 22 (42.31%) 9 (17.31%)
Non-triple negative 11 (21.15%) 16 (30.77%)
Total 33 25
HER2 + 7 (12.07%) 12 (20.69%)
HER2 - 26 (44.83%) 13 (22.41%)
Total 33 25
>1 cm 27 (46.55%) 16 (27.59%)
≤1 cm 8 (13.79%) 7 (12.07%)
35 23
Grade I 5 (8.62%) 4 (6.90%)
Grade II 12 (20.69%) 12 (20.69%)
Grade III 16 (27.59%) 9 (15.52%)
Total 33 25
Vascular invasion 7 (12.07%) 7 (12.07%)
No vascular invasion 26 (44.83%) 18 (31.03%)
Total 33 25
Relapsed 25 (43.10%) 20 (30.48%)
Not relapsed 8 (13.79%) 5 (8.62%)
Total 33 25
Relapsed 0–6 months 17 (37.78%) 14 (31.11%)
Relapsed 6–12 months 4 (8.89%) 3 (31.03%)
Relapsed >12 months 4 (8.89%) 3 (31.03%)
Total 25 20
Mitotic indexa 1 4 (6.90%) 2 (3.45%)
Mitotic index 2 7 (12.07%) 8 (13.79%)
Mitotic index 3 22 (42.31%) 15 (25.86%)
Total 33 25
aMitotic index of the histological grading system [27].were found comparing mTOR and p-mTOR expression in
relation to ER and PR phenotype.
Western blot analysis
To validate the antibodies used in immunohistochemistry
and to further investigate mTOR expression in TN-FMC,
Western blot analysis of mTOR, p-mTOR, ER, PR and
HER2 was performed on FMC cell lines (Figure 4). A
specific 289 kDa band corresponding to human mTOR
was found in all cell lines analysed. A specific 286 kDa
band corresponding to phospho-mTORSer2448-49F9
was visible in all cell lines, with the strongest expressionpression of mTOR and p-mTOR
P p-mTOR+ p-mTOR - P
n (%) n (%)
0.03 24 (41.38%) 7 (12.07%) 0.0005
8 (13.79%) 19 (32.76%)
32 26
mTOR + 24 (41.38%) 8 (13.79%) 0.0032
mTOR - 9 (17.31%) 17 (29.31%)
32 26
* ***
0.0479 4 (6.9%) 15 (25.86%) 0.0005
28 (48.28%) 11 (18.97%)
32 26
>0.05 22 (42.31%) 20 (30.48%) 0.05
10 (17.24%) 6 (10.34%)
32 26
>0.05 4 (6.90%) 5 (8.62%) >0.05
14 (24.14%) 10 (17.24%)
14 (24.14%) 11 (21.15%)
32 26
>0.05 6 (10.34%) 8 (13.79%) >0.05
26 (44.83%) 18 (31.03)
32 26
>0.05 17 (29.31%) 28 (48.28%) >0.05
7 (12.07%) 6 (10.34%)
24 34
>0.05 9 (20.00%) 22 (48.89%) >0.05
4 (8.89%) 3 (31.03%)
4 (8.89%) 4 (31.03%)
17 28
>0.05 3 (5.17%) 3 (5.17%) >0.05
8 (13.79%) 7 (12.07%)
21 (36.21%) 16 (27.59%)
32 26
Figure 4 Western blot. a. Western blot analysis of HER2, oestrogen receptor α (ERα), progesterone receptor (PR), mTOR and p-mTOR expression
in FYCp (lane 1), P248m (lane 2), FMCp (lane 3), FMCm (lane 4), FKNp (lane 5) and FNNm (lane 6) cell lines. α Tubulin expression was used as the
loading control. b. Measure of band intensity normalized to α tubulin. Error bars demonstrate standard deviation.
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kDa) was also present in the FYC cell line, while specific
116 kDa (B form) and 81 kDa (A form) double bands
corresponding to PR were present in the FNNm cell
line. HER2 band (185 kDa) was detected in all of the
FMC cell lines. The FKNp, FMCm, P248m and FYCp
cell lines demonstrated higher expression of HER2 than
the FYCp, FMCp and FNNm cell lines; cell line derived
from the metastatic tumor (FMCm) shows a higher
expression of HER2 compared to the cell line derived
from the primary tumor (FMCp).
Discussion
This study provides the first evidence that felines also
have a subset of mammary carcinoma that is defined by
the lack of immunohistochemical ER and PR expression
and a lack of HER2 overexpression, which we identify as
TN FMC. Similar to human breast cancer, these tumours
demonstrate high expression of mammalian target of ra-
pamycin (mTOR). Human TNBCs have a poor prognosis,
because such cancers have no effective therapeutic targets,
e.g. ER for endocrine therapy or human epidermal growth
factor receptor 2 receptors for anti-HER2 therapy [35-37].
For these reasons, several efforts are underway to better
characterize this type of tumour to develop new targeted
therapies and to identify a new animal model for compara-
tive oncology.
Among spontaneous tumours occurring in domestic
animals, feline mammary tumour is widely considered an
excellent model for human breast cancer. In particular, thehigh percentage of FMCs negative for ER and PR, ranging
from 37% [20] to 54.2% [21], makes this tumour a suitable
model of breast cancer hormone independent subtype
[24]. Moreover we and others [19,22,23] showed that
HER2 is expressed from 39% to 56.3% and is a negative
prognostic factor [23] similar to human breast cancer
(20-30%) [24] while Rasotto and colleagues [25] demon-
strated that only the 5.5% of FMCs was HER2 positive
and it is not a prognostic factor in FMCs. This discrepancy
might be due to the use of different antibodies, criteria of
evaluation and other issues related to discordant study
protocols [38] and, considering the potential importance
of FMCs as model for human breast cancer, a standardised
method for the detection of HER2 expression and cellu-
lar localisation in feline mammary tumours is urgently
needed. In addition, our group has demonstrated that
p-AKT is expressed in a high percentage of FMCs and
correlated to poor prognosis [22], suggesting that the
PI3K/AKT/mTOR pathway is activated and associated
with oncogenesis in the feline species, which is similar
to that in humans [14] and recently also demonstrated in
canine tumour cells [39] These assumptions prompted us
to better understand the involvement of mTOR in FMC.
The IHC results obtained in this study demonstrated
that there is a FMC tumour subtype that we can charac-
terise as TN FMC since 53.4% of feline FMCs do not ex-
press ER and PR and also lack HER2 overexpression.
These data are consistent with the description of human
TNBCs [1] even if more expressed and confirm the pres-
ence of a new entity in feline mammary oncology.
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TNBC therapies is the inhibition of the PI3K/AKT/mTOR
pathways, particularly mTOR, which is more frequently
expressed in TN cancer compared with its non-TN coun-
terparts [3] and is considered to be a potential anticancer
therapy molecular target [9,13-15]. We have previously
shown that the PI3K/AKT/PTEN pathway was activated
in feline mammary carcinoma and correlated with poor
prognosis [22], while there are no scientific data demon-
strating mTOR expression in FMC tissues and cell lines
with respect to the TN phenotype and AKT activation as
demonstrated in humans. To elucidate whether feline
mTOR was also phosphorylated by AKT, we evaluated
both mTOR and p-mTOR at serine 2448, which repre-
sents a specific p-AKT phosphorylation site.
In this study, we observed that the 56.9% and 55.2% of
FMC samples expressed mTOR and p-mTOR respectively
and we found a statistical association between mTOR and
p-mTOR expression in the same samples (P <0.005)
analysed. These data suggest that the mTOR protein is
widely present in feline mammary carcinomas in its
Ser2448 phosphorylated form, which is regulated by
AKT [6]. These results are similar to human breast cancer,
in which mTOR is expressed in 47% of cases [3] while
p-mTOR expression has been reported in 24% to 69.7%
of cases [14,40].
The correlation between mTOR and p-mTOR expression
and prognosis, tumour histological grading, vascular inva-
sion, tumour size and mitotic index did not demonstrated
any statistically significant correlations, suggesting that
neither mTOR nor its putative active form (p-mTOR) have
a prognostic role in feline mammary carcinoma. In human
breast cancer, the prognostic significance of p-mTOR
expression is still controversial [3,14,41]. With regard to
expression in TN-FMC, this study observed that mTOR
and p-mTOR expression are statistically associated with
the TN phenotype. This evidence is consistent with the
results described in humans by Walsh and colleagues [3]
that observed a higher expression of p-mTOR in TNBCs.
As shown in Table 1 we investigated if the high expression
of m-TOR and p-mTOR founded in our samples was
correlated to HER2 expression and we found that samples
HER2 negatives are highly correlated to samples p-mTOR
(P = 0.0005) and m-TOR (P = 0.0479) positives. These data
confirm as in human [3] that p-mTOR is statistically
correlated to triple negative phenotype. Interestingly, we
found an opposite correlation between HER2 expression
and mTOR phosphorylation. As during progression of
cancers selection operates favouring cells with activated
oncogenes, it is not surprising that cells showing the acti-
vation of a HER2 downstream signal, such as mTOR, do
not require the simultaneous activation of the upstream
signal, i.e. HER2. This for example also occurs in cells
showing either RAS or RAF mutations, which aremutually exclusive in colorectal cancer [42] and melan-
oma [43].
As described in results, western blot was performed
mainly to identify the specify of antibodies and the cor-
responding proteins expression in feline mammary cells
lines. The expression of PR, ER, HER2, mTOR,
p-mTOR was confirmed by immunocytochemistry on
each cellular monolayer (data not shown). On the basis
of western blot analysis we can assess that 4/6 cell lines
are negative for PR and ER, suggesting the non
hormonal-dependent behavior of feline mammary car-
cinomas. Only FMCp cell line resulted ER and PR nega-
tive and with a low level of HER2 showing a triple
negative behavior. All cell lines demonstrated high
mTOR and p-mTOR expression with a higher expres-
sion of p-mTOR in the FMCp, FMCm and FNNm cell
lines. The higher mTOR phosphorylation in the
metastasis-derived cell line (FMCm) compared with its
primary counterpart (FMCp) suggests a significant in-
volvement of p-mTOR in metastasis, invasion and FMC
tumor progression, such as in human breast cancer
[14,44].
mTOR is considered a potential target for anti-tumor
therapies [14,44] due to its role in breast cancer progres-
sion. The finding shown here, demonstrating the strong
activation of mTOR in triple negative FMC, suggests
that this tumor may be a suitable model to test innova-
tive therapies against the human TNBCs.
Conclusions
Spontaneous tumours occurring in companion animals
represent a significant resource for models to study innova-
tive therapies for human cancer and feline mammary car-
cinoma is considered a suitable model for human hormone
independent breast cancer. In this study, we demonstrate
that there is also a FMC subset defined as TN FMC, which
is characterised by a statistically significant association with
m-TOR and p-mTOR expression as demonstrated in
human breast cancer.
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